ORLANDO, FL, USA (UroToday.com) - When androgen deprivation therapy (ADT) for prostate cancer was first developed, life expectancy for men with advanced disease was short and the systemic effects were of limited relevance. Men are now living longer durations on ADT due to earlier intervention in the PSA era as well as multiple novel therapeutics that prolong survival.
Hot flashes are a common side effect of traditional ADT. Estrogenic compounds, such as DES, have been shown to decrease hot flashes in men with advanced prostate cancer since these hot flashes are a result of lower estrogen levels. GTx-758 is a selective ERα agonist that decreases serum total testosterone (T) and free T, along with PSA and increases SHBG levels.
Herein, we compare the effects of GTx-758 and leuprolide on hot flashes, one of the earliest and most common side effects in men on ADT....Click here to enlarge and view the poster.
(Click thumbnail to enlarge poster)
Presented by Evan Y. Yu,1 Marc Gittelman,2 Thomas E. Keane,3 Ronald Tutrone,4 Laurence Belkoff,5 Robert Given,6Joel Bass,7 Franklin Chu,8 Mike Gambla,9 Franklin Gaylis,10 James Bailen,11 Robert H. Getzenberg,12 Christopher Coss,12 Michael L. Hancock,12 James T. Dalton,12 and Mitchell S. Steiner12 at the 2013 Genitourinary Cancers Symposium - February 14 - 16, 2013 - Rosen Shingle Creek - Orlando, Florida USA
1Univ of Washington, Seattle, WA USA; 2South FL Medical Research, Aventura, FL USA; 3MUSC, Charleston, SC USA 4Chesapeake Urology, Towson, MD USA; Research Associates 5UCSEPA, Bala Cynwyd, PA USA; 6Urology of VA, PLLC, Virginia Beach, VA USA 7AMP of NY – Urology, Syracuse, NY USA; 8San Bernardino Urological Assoc., San Bernardino, CA USA; 9Central Urology Group, Columbus, OH USA 10Genesis Healthcare Partners, San Diego, CA USA; 11First Urology, PSC, Jeffersonville, IN USA; 12GTx, Inc., Memphis, TN USA
View Full 2013 GU Cancers Symposium Coverage
